Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutic

HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Citius Pharmaceuticals (NASDAQ:CTX

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biop

Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribin

Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutic

Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonst

Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.38) per share which missed the analyst

(Editor’s note: The future prices of benchmark tracking ETFs and headline were updated in the story.

Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPH

U.S. stock futures slightly lower. UiPath joins S&P Midcap 400, Agios receives FDA approval, Can

Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.11) per share which beat the analyst co

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR), a bi

D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy

Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIRCRANF

  On Tuesday, 386 stocks made new 52-week lows.

Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company cease

U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in

Gainers Biodexa Pharmaceuticals (NASDAQ: BDRX) shares rose 76% to $0.8276 in pre-market trading a

Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced n